Cancer vaccines: current directions and perspectives in prostate cancer

about

Targeting inhibitory pathways in cancer immunotherapy.Prostate cancer as a model for tumour immunotherapy.Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis

P2860

Q33950640-F728248F-BE31-4818-8955-8108A24231BE Q34856875-129F8763-6000-4F10-80E5-29AA0A904647 Q36579336-8073B3BF-F96D-4F2D-9EFF-93D5F58A8F77

P2860

Cancer vaccines: current directions and perspectives in prostate cancer

Item

http://www.wikidata.org/entity/Q36368968

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Cancer vaccines: current directions and perspectives in prostate cancer

@ast

Cancer vaccines: current directions and perspectives in prostate cancer

@en

type

Item

label

Cancer vaccines: current directions and perspectives in prostate cancer

@ast

Cancer vaccines: current directions and perspectives in prostate cancer

@en

prefLabel

Cancer vaccines: current directions and perspectives in prostate cancer

@ast

Cancer vaccines: current directions and perspectives in prostate cancer

@en

P1476

Cancer vaccines: current directions and perspectives in prostate cancer

@en

P2093

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Mahsa Mohebtash

http://www.w3.org/2001/XMLSchema#string

Philip M Arlen

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

Theresa Ferrara

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Standard treatments induce antigen-specific immune responses in prostate cancer.

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Quantitating therapeutically relevant T-cell responses to cancer vaccines.

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.

Activation of thymic regeneration in mice and humans following androgen blockade.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

P304

31-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19169957

http://www.w3.org/2001/XMLSchema#string

P932

3488286

http://www.w3.org/2001/XMLSchema#string

Cancer vaccines: current directions and perspectives in prostate cancer

about

P2860

P2860

Cancer vaccines: current directions and perspectives in prostate cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932